Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Inhibition of activity tryptophan hydroxylase-1 - the new conception in the treatment of mineral and bone disorders in chronić reanal failure.

2013/09/B/NZ7/00046

Keywords:

tryptophan hydroxylase-1 inhibitor serotonin bone and mineral disorders experimental chronic renal failure

Descriptors:

  • NZ7_14: Pharmacy, pharmacotherapy, pharmacology

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Uniwersytet Medyczny w Białymstoku, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

woj. podlaskie

Other projects carried out by the institution 

Principal investigator (from the host institution):

prof. Krystyna Pawlak 

Number of co-investigators in the project: 9

Call: OPUS 5 - announced on 2013-03-15

Amount awarded: 729 685 PLN

Project start date (Y-m-d): 2014-03-21

Project end date (Y-m-d): 2018-03-20

Project duration:: 48 months (the same as in the proposal)

Project status: Project settled

Equipment purchased [PL]

  1. Oprogramowanie Biokinetica v.4.0 (9 000 PLN)
  2. Aparat spektrofotometr UV-Vis NanoDrop2000.
  3. Zamrażarka niskotemperaturowa z awaryjnym systemem chłodzenia (CO2), pojemność 500 l, stelaże, pojemniki niskotemperaturowe. (95 000 PLN)

Information in the final report

  • Publication in academic press/journals (5)
  • Articles in post-conference publications (8)
  1. Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats.
    Authors:
    Pawlak D, Domaniewski T, Sieklucka B, Jakuc M, Pawlak K.
    Academic press:
    Biochim Biophys Acta Mol Basis Dis (rok: 2019, tom: 1865, strony: 165528), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.bbadis.2019.08.004 - link to the publication
  2. The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease.
    Authors:
    Pawlak D, Domaniewski T, Znorko B, Oksztulska-Kolanek E, Lipowicz P, Doroszko M, Karbowska M, Pawlak K.
    Academic press:
    Bone (rok: 2017, tom: 105, strony: 45301), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.bone.2017.08.004 - link to the publication
  3. The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats.
    Authors:
    Pawlak D, Domaniewski T, Znorko B, Pawlak K
    Academic press:
    Expert Opin Ther Targets (rok: 2019, tom: 23, strony: 353-364), Wydawca: Taylor & Francis Online
    Status:
    Published
    DOI:
    10.1080/14728222.2019.1586883 - link to the publication
  4. The association between elevated levels of peripheral serotonin and its metabolite - 5-hydroxyindoleacetic acid and bone strength and metabolism in growing rats with mild experimental chronic kidney disease
    Authors:
    Pawlak D, Oksztulska-Kolanek E, Znorko B, Domaniewski T, Rogalska J, Roszczenko A, Brzóska MM, Pryczynicz A, Kemona A, Pawlak K
    Academic press:
    PLoS One (rok: 2016, tom: 2016;11(10), strony: -), Wydawca: Public Limbrary of Science
    Status:
    Published
    DOI:
    10.1371/journal.pone.0163526 - link to the publication
  5. LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys.
    Authors:
    Pawlak D, Znorko B, Kalaska B, Domaniewski T, Zawadzki R, Lipowicz P, Doroszko M, Łebkowska U, Grabowski P, Pawlak K
    Academic press:
    Bone (rok: 2018, tom: 113, strony: 124-136), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.bone.2018.05.022 - link to the publication
  1. LP533401 treatment and disturbance of calciotropic hormones resulted in dysregulation of serotonin-dependent genes and reduction of osteoblast proliferation/differentiation in rats with chronic kidney disease.
    Authors:
    Pawlak K, Domaniewski T, Sieklucka B, Jakuc M, Pawlak D
    Conference:
    7th Central European Congress on Osteoporosis and Osteoarthritis (rok: 2019, ), Wydawca: Komitet Organizacyjny Kongresu
    Data:
    konferencja 27-28 wrzesień
    Status:
    Published
  2. Wpływ LP533401 na wydalanie fosforanów i ekspresję genów zaangażowanych w reabsorpcję fosforanów w nerce w modelu eksperymentalnej niewydolności nerek u szczura.
    Authors:
    Pawlak K, Domaniewski T, Znorko B, Pawlak D.
    Conference:
    XXIII Naukowy Zjazd Polskiego Towarzystwa Farmaceutycznego (rok: 2017, ), Wydawca: Polskie Towarzystwo Farmaceutyczne, Wydział Farmaceutyczny, Uniwersytet Jagielloński-Collegium Medicum
    Data:
    konferencja 19-22 wrzesień
    Status:
    Published
  3. The influence of tryptophan hydroxylase inhibitor LP533401 on kynurenine concentration in bone tissue in the experimental model of chronic kidney disease.
    Authors:
    Kalaska B, Mor A, Sieklucka B, Domaniewski T, Zawadzki R, Lebkowska U, Pawlak K, Pawlak D
    Conference:
    56th ERA-EDTA Congress (rok: 2019, ), Wydawca: Nephrol Dial Transplant 2019, 34 (suppl.1), FP443
    Data:
    konferencja 13-16 czerwiec
    Status:
    Published
  4. Wpływ terapii LP533401 na ekspresję transporterów wapnia w nerce w modelu eksperymentalnej niewydolności nerek u szczura.
    Authors:
    Pawlak K, Domaniewski T, Znorko B, Grabowski P, Pawlak D.
    Conference:
    XXIV Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Nefrologicznego (rok: 2018, ), Wydawca: Polskie Towarzystwo Nefrologiczne
    Data:
    konferencja 21-23 czerwiec
    Status:
    Published
  5. Low expression of sclerostin (Sost) gene in the femur of rats with chronic kidney disease treated with inhibitor of type 1 tryptophan hydroxylase is associated with the improvement of femoral mineral status.
    Authors:
    Pawlak D, Domaniewski T, Sieklucka B, Jakuc M, Pawlak K.
    Conference:
    7th Central European Congress on Osteoporosis and Osteoarthritis (rok: 2019, ), Wydawca: Komitet Organizacyjny Kongresu
    Data:
    konferencja 27-28 września
    Status:
    Published
  6. The treatment with LP533401 improved bone mineral density in rats with experimental chronic kidney disease.
    Authors:
    Pawlak K, Znorko B, Zawadzki R, Łebkowska U, Domaniewski T, Pawlak D
    Conference:
    Osteoporosis Conference 2016, Birmingham, UK, 7-9 November 2016. (rok: 2016, ), Wydawca: Springer
    Data:
    konferencja 7-9 listopad 2016
    Status:
    Published
  7. Tryptophan hydroxylase-1 inhibitor – LP533401 by decrease serum phosphorus affected bone mineral density in experimental chronic kidney disease
    Authors:
    Pawlak D, Znorko B, Zawadzki R, Łebkowska U, Domaniewski T, J Rogalska, Brzoska M, Pawlak K
    Conference:
    Osteoporosis Conference 2016, Birmingham, UK, 7-9 November 2016. (rok: 2016, ), Wydawca: Springer
    Data:
    konferencja 7-9 listopada 2016
    Status:
    Published
  8. Wpływ inhibitora hydroksylazy tryptofanu - LP533401 na gospodarkę witaminy D w doświadczalnym modelu niewydolności nerek u szczura.
    Authors:
    Pawlak D, Domaniewski T, Znorko B, Mor A, Pawlak K.
    Conference:
    XXIV Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Nefrologicznego (rok: 2018, ), Wydawca: Polskie Towarzystwo Nefrologiczne
    Data:
    konferencja 21-23 czerwiec
    Status:
    Published